Interact to see
Advertisement
Advertisement
ADNRX vs FSMAX
ADNRX vs FSMAX Comparison
Open Charts ADNRX vs FSMAX
American Beacon ARK Transfmt Innov R6
Price$22.19
Change-$0.09 (-0.40%)
VolumeN/A
Net Assets220.9M
Fidelity Extended Market Index
Price$100.74
Change+$0.01 (+0.01%)
VolumeN/A
Net Assets41.05B
ADNRX vs FSMAX Comparison Chart in %
Loading...
View a ticker or compare two or three
VS
VS
ADNRX vs. FSMAX commentary
Sep 18, 2025
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADNRX is a Hold and FSMAX is a Buy.
FUNDAMENTALS
Fundamentals
FSMAX has more cash in the bank: 41B vs. ADNRX (221M). FSMAX pays higher dividends than ADNRX: FSMAX (0.44) vs ADNRX (0.00). ADNRX was incepted earlier than FSMAX: ADNRX (5 years) vs FSMAX (14 years). ADNRX (1.13) is less costly to investors than FSMAX (0.04). ADNRX is a more actively managed with annual turnover of: 38.00 vs. FSMAX (9.00). ADNRX (0) and FSMAX (0) have matching initial minimum investment requirements. ADNRX annual gain was more profitable for investors over the last year : 75.14 vs. FSMAX (18.16).
| ADNRX | FSMAX | ADNRX / FSMAX | |
| Total Expense Ratio | 1.00 | 0.04 | 2,857% |
| Annual Report Gross Expense Ratio | 1.13 | 0.04 | 3,229% |
| Fund Existence | 5 years | 14 years | - |
| Gain YTD | 42.335 | 10.838 | 391% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 221M | 41B | 1% |
| Annual Yield % from dividends | 0.00 | 0.44 | - |
| Returns for 1 year | 75.14 | 18.16 | 414% |
| Returns for 3 years | 77.52 | 57.15 | 136% |
| Returns for 5 years | N/A | 60.51 | - |
| Returns for 10 years | N/A | 103.14 | - |
View a ticker or compare two or three
VS
VS
Interact to see
Advertisement
Advertisement
Interesting Tickers